Previous 10 | Next 10 |
Amarin Looks Promising Ahead of Full Year Results, Receives Upgrade Amarin ( AMRN ) received a boost when Citigroup upgraded its stock to Buy. The target price for the stock has been set at $24 a share, showing considerable upside from the current market price, but still below its recent h...
Gainers: Bellerophon Therapeutics (NASDAQ: BLPH ) +144% . More news on: Bellerophon Therapeutics, Inc., Brickell Biotech, Inc., Wanda Sports Group Company Limited, Stocks on the move, , Read more ...
Bellerophon Therapeutics (NASDAQ: BLPH ) +67% on positive top-line data from a recently completed acute, intra-patient, dose escalation, hemodynamics study of INOpulse for the treatment of Pulmonary Hypertension associated with Pulmonary Fibrosis. More news on: Bellerophon Therape...
Thinly traded nano cap Bellerophon Therapeutics (NASDAQ: BLPH ) jumps 61% premarket on robust volume in reaction to positive topline data from a 16-subject Phase 2 clinical trial, PULSE-PHPF-002 , evaluating INOpulse in patients with pulmonary hypertension associated with pulm...
WARREN, N.J., Feb. 18, 2020 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company, today announced positive top-line data from a recently completed acute, intra-patient, dose e...
WARREN, N.J., Feb. 07, 2020 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company, today announced the filing of a certificate of amendment to its amended and restated certific...
Bellerophon Therapeutics (NASDAQ: BLPH ) is up 36% on the heels of positive top-line results from Cohort 2 of its ongoing Phase 2/3 study (iNO-PF) of INOpulse for the treatment of Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD). More news on: Bellero...
Statistically Significant Improvement Demonstrated in Moderate to Vigorous Physical Activity Bellerophon Intends to Initiate Pivotal Phase 3 in First Quarter of 2020 Company Enters Into $10M Convertible Financing Facility Led By Existing Institutional Shareholders, Extending Cas...
WARREN, N.J., Nov. 12, 2019 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company, today announced positive initial data from an acute, dose escalation, clinical study (PHPF-00...
WARREN, N.J., Nov. 07, 2019 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company, is presenting data from Cohort 1 of its ongoing Phase 2/3 randomized, double-blind, placebo-c...
News, Short Squeeze, Breakout and More Instantly...
Bellerophon Therapeutics Inc. Company Name:
BLPH Stock Symbol:
NASDAQ Market:
Bellerophon Therapeutics Inc. Website:
3D Systems Corporation (DDD) is expected to report $-0.11 for Q1 2024 ZW Data Action Technologies Inc. (CNET) is expected to report for Q1 2024 Celularity Inc. (CELU) is expected to report for Q1 2023 DMK Pharmaceuticals Corporation (DMKPQ) is expected to report for Q1 2024 Atlant...
ADDvantage Technologies Group Inc. (AEYGQ) is expected to report for Q1 2024 ContraFect Corporation (CFRXQ) is expected to report for Q1 2024 American Clean Resources Group Inc (ACRG) is expected to report for Q1 2024 Atlantic Lithium Ltd Ord Fully Paid (ALLIF) is expected to report f...
Windtree Therapeutics Inc. (WINT) is expected to report for Q1 2024 CohBar Inc. (CWBR) is expected to report for Q1 2024 hopTo Inc (HPTO) is expected to report for Q1 2024 Bitech Technologies Corporation (BTTC) is expected to report for Q1 2024 Roadzen Inc. (RDZN) is expected to r...